Gedatolisib efficacy across mutant and wild-type PIK3CA BC cells could be due to the direct inhibition of multiple kinases of the PAM pathway, including all Class I isoforms of PI3K and the mTORC1/2 complexes. Here, PIK3CA is linked to breast cancer.